Published in Gastroenterology Week, May 8th, 2006
"IFN alpha is an approved treatment option for patients chronically infected with the hepatitis B and C viruses. Additionally, there is an indication for tumor therapy," wrote C. Liedtke and colleagues, Medizinische Hochschule Hannover. "The exact mechanisms underlying the antiviral and antitumor effects of IFN alpha are not completely understood. In this study, we investigated if...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.